Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FABER-Net

Financiado

Cerrado

FABER Net A unique network of labs dedicated to the diagnosis of allergies usin...

FABER Net A unique network of labs dedicated to the diagnosis of allergies using the innovative FABER test Allergies are the most common chronic disease: with >1B people affected globally, of which >150M in Europe, today allergies are a worldwide epidemic. Besides clinical symptoms such as rhinitis, asthma and atopic eczema, allergies... ver más

31/08/2019

ADL

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ALLERGY DATA LABORATORIES SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-08-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

ADL

50.00K€ | Lider

INFOPORT VALENCIA

210.97K€ | Participante

S2 GRUPO DE INNOVACION EN PR...

389.86K€ | Participante

Proyectos interesantes

EUIN2017-87308

Medical Technol...

Health Informat...

23K€ Cerrado

ARM-B

Medical Technol...

Data Science

71K€ Cerrado

MYA

Medical Technol...

Data Science

71K€ Cerrado

RTC-2015-3273-1

Medical Technol...

Health Informat...

376K€ Cerrado

DIGITALIZACIÓN Y ANÁLISIS DE SUPERFICIES CUTÁ...

Medical Technol...

Data Science

598K€ Cerrado

INNOPRICK

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2019-04-10
Fecha Fin: 2019-08-31

Líder del proyecto

ALLERGY DATA LABORATORIES SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Allergies are the most common chronic disease: with >1B people affected globally, of which >150M in Europe, today allergies are a worldwide epidemic. Besides clinical symptoms such as rhinitis, asthma and atopic eczema, allergies cause distress in those affected, who live in fear of an asthma attack, anaphylactic shock, or death from an allergic reaction. In addition, allergies have high costs for businesses and society: in the EU, work absenteeism of allergic patients costs €55-151B/year, while families with one allergic child or adult spend an extra €3,900-8,100/year. A high-quality and reliable allergy diagnosis is essential to identify the best treatment option for allergic patients and improve their health, and also to reduce costs. Today there are >3000 molecules known to cause allergies, but current methods for diagnosis are not able to test a high number of allergens, at a reasonable price and in a short time; also, most of them are invasive and present some risks for the patients. On top of this, every year new allergens are discovered, but they can’t be included in diagnostic tests for technical and economic reasons. To overcome these limitations ADL has created the FABER test: a multiplex system for allergy diagnosis that can test 301 allergens at the time - the highest number currently available. This is a flexible system based on nanotechnology in which the number of allergens can be increased when new ones are available. ADL aims to expand in Europe and then worldwide the network of labs that provide FABER allergy diagnosis at the most local level and with ADL’s highest testing quality. Thanks to this network (FABER-Net), the FABER test will be available for many patients suffering from allergies, who will have a more informative diagnosis, which in turn will allow a more personalized and effective treatment. This will improve the patients’ health and reduce their absenteeism from work, thus cutting costs in healthcare and associated with work absence

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores